Go Pro
→ The Starlink of Energy (From Monument Traders Alliance) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.97 0.00 (0.00%)
As of 12:03 PM Eastern
Compare

BPCR vs. FWT, BRIG, LGT, RIV, and SGEM

Should you buy BioPharma Credit stock or one of its competitors? MarketBeat compares BioPharma Credit with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioPharma Credit include Foresight Technology VCT (FWT), BlackRock Income and Growth (BRIG), Lighthouse Group (LGT), River and Mercantile Group (RIV), and ScotGems (SGEM).

How does BioPharma Credit compare to Foresight Technology VCT?

BioPharma Credit (LON:BPCR) and Foresight Technology VCT (LON:FWT) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled Foresight Technology VCT'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
Foresight Technology VCT Neutral

BioPharma Credit has higher revenue and earnings than Foresight Technology VCT. Foresight Technology VCT is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.09
Foresight Technology VCT£64K678.42£23.15M-£0.80N/A

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Comparatively, 0.3% of Foresight Technology VCT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Foresight Technology VCT has a net margin of 255.13% compared to BioPharma Credit's net margin of 92.62%. BioPharma Credit's return on equity of 11.29% beat Foresight Technology VCT's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
Foresight Technology VCT 255.13%-4.85%3.17%

BioPharma Credit has a beta of 0.22095597, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Foresight Technology VCT has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Summary

BioPharma Credit beats Foresight Technology VCT on 8 of the 11 factors compared between the two stocks.

How does BioPharma Credit compare to BlackRock Income and Growth?

BioPharma Credit (LON:BPCR) and BlackRock Income and Growth (LON:BRIG) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. BlackRock Income and Growth pays an annual dividend of GBX 7.70 per share and has a dividend yield of 3.3%. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. BlackRock Income and Growth pays out 22.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

31.3% of BioPharma Credit shares are held by institutional investors. Comparatively, 0.7% of BlackRock Income and Growth shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Comparatively, 3.8% of BlackRock Income and Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioPharma Credit has a net margin of 92.62% compared to BlackRock Income and Growth's net margin of 88.25%. BlackRock Income and Growth's return on equity of 14.31% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
BlackRock Income and Growth 88.25%14.31%2.59%

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled BlackRock Income and Growth'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
BlackRock Income and Growth Neutral

BioPharma Credit has a beta of 0.22095597, indicating that its share price is 78% less volatile than the broader market. Comparatively, BlackRock Income and Growth has a beta of 0.62268645, indicating that its share price is 38% less volatile than the broader market.

BioPharma Credit has higher revenue and earnings than BlackRock Income and Growth. BioPharma Credit is trading at a lower price-to-earnings ratio than BlackRock Income and Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.09
BlackRock Income and Growth£7.07M6.08£6.90M£34.866.62

Summary

BlackRock Income and Growth beats BioPharma Credit on 7 of the 13 factors compared between the two stocks.

How does BioPharma Credit compare to Lighthouse Group?

BioPharma Credit (LON:BPCR) and Lighthouse Group (LON:LGT) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled Lighthouse Group'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
Lighthouse Group Neutral

31.3% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioPharma Credit has a net margin of 92.62% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
Lighthouse Group N/A N/A N/A

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.09
Lighthouse Group£53.42M0.00N/A£1.80N/A

Summary

BioPharma Credit beats Lighthouse Group on 8 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

River and Mercantile Group (LON:RIV) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

31.3% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
River and Mercantile Group£74.82M0.00N/A-£2.20N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

BioPharma Credit has a net margin of 92.62% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
River and Mercantile GroupN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

In the previous week, River and Mercantile Group's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
River and Mercantile Group Neutral
BioPharma Credit Neutral

Summary

BioPharma Credit beats River and Mercantile Group on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

ScotGems (LON:SGEM) and BioPharma Credit (LON:BPCR) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

31.3% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScotGems£5.07M0.00N/A£0.07N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.09

BioPharma Credit has a net margin of 92.62% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
ScotGemsN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 721.6%. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, ScotGems' average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
ScotGems Neutral
BioPharma Credit Neutral

Summary

BioPharma Credit beats ScotGems on 9 of the 10 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditCapital Markets IndustryFinance SectorLON Exchange
Market Cap£10.89M£5.55B£14.03B£2.87B
Dividend Yield7.23%7.46%5.91%6.13%
P/E Ratio0.0938.2429.34369.49
Price / Sales0.081,242.89511.8683,955.53
Price / Cash1.1948.2339.3227.89
Price / Book0.013.743.747.07
Net Income£10.42B£417.17M£1.31B£5.89B
7 Day PerformanceN/A1.27%1.11%1.18%
1 Month Performance1.04%-0.46%0.46%0.90%
1 Year Performance12.27%6.59%13.14%75.31%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.97
flat		N/A+11.2%£10.89M£132.06M0.09N/A
FWT
Foresight Technology VCT
N/AGBX 85.50
-2.8%		N/AN/A£43.14M-£2.30MN/A375
BRIG
BlackRock Income and Growth
N/AGBX 231.56
-0.2%		N/A+7.6%£43.06M£7.07M6.64N/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
This AI fund sends investors payouts every Thursday
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
A Wall Street Veteran's Weekly Trade for Any Market Condition
Dave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
This under $7 stock could be.
Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...
Freedom Financial | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel